journal
MENU ▼
Read by QxMD icon Read
search

Atherosclerosis. Supplements

journal
https://www.readbyqxmd.com/read/29153764/corrigendum-to-monascus-purpureus-for-statin-and-ezetimibe-intolerant-heterozygous-familial-hypercholesterolaemia-patients-a-clinical-study-atherosclerosis-supplements-30c-2017-86-91
#1
Claudia Stefanutti, Fabio Mazza, Dario Mesce, Claudia Morozzi, Serafina Di Giacomo, Marco Vitale, Mario Pergolini
No abstract text is available yet for this article.
November 16, 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29096869/prospective-crossover-study-for-a-standardized-comparison-of-the-dextrane-sulfate-whole-blood-and-plasma-apheresis-system-in-patients-with-cardiovascular-disease-and-severe-dyslipidemia
#2
Wolfgang Ramlow, Heinrich Prophet, Grit Waitz
BACKGROUND AND AIMS: The objective of this study was a standardized comparison of the safety and effectiveness of the Kaneka (Kaneka Corporation, Osaka, Japan) whole blood (Liposorber DL-100) and plasma (Liposorber LA-15) lipoprotein apheresis (LA) system to optimize the individual therapy of patients with cardiovascular disease and severe dyslipidemia. METHODS: Six chronic LA patients with a pre-treatment LDL-C < 6 mmol/l in steady state received a total of three treatments with the LA-15 device, followed by three treatments with the DL-100 device or vice versa...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29096868/impact-of-double-filtration-plasmapheresis-on-adhesion-molecules-levels-in-patients-with-stable-coronary-heart-disease-after-coronary-stenting
#3
Valerii V Tishko, Alexey A Sokolov, Andrei N Belskih, Andrei M Ivanov, Marina E Meshkova, Tatyana S Skorinova
OBJECTIVE AND METHODS: Endothelial dysfunction and inflammatory reaction at the site of damage plays a key role in the formation of neointimal hyperplasia, and in the progression of atherosclerosis. The initiating role in these processes is assigned to adhesion molecules. We studied the dynamics of the level of adhesion molecules soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular adhesion molecule-1 (sVCAM-1), soluble form of the molecule platelet adhesion and endothelial type-1 (sPECAM-1), sL-, sP-, sE-selectins during double filtration plasmapheresis (DFPP) with use of plasma fractionators (PF) Cascadeflo EC-50W and EC-40W (Asahi Kasei Medical Co...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29096867/the-efficacy-of-anti-pcsk9-antibodies-results-from-recent-trials
#4
Ioanna Gouni-Berthold
The serine protease proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low-density lipoprotein (LDL) receptor (LDLR) and directs it to the lysosome for degradation. This results in decreased numbers of LDLR available on the cell surface to bind LDL particles and remove them from the circulation and a subsequent increase in circulating LDL-cholesterol (LDL-C) concentrations. Since the role PCSK9 plays in LDL-C metabolism has been discovered in 2003, there have been major efforts in finding efficient and safe methods to inhibit it...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29096866/monascus-purpureus-for-statin-and-ezetimibe-intolerant-heterozygous-familial-hypercholesterolaemia-patients-a-clinical-study
#5
Claudia Stefanutti, Fabio Mazza, Dario Mesce, Claudia Morozzi, Serafina Di Giacomo, Marco Vitale, Mario Pergolini
BACKGROUND: Hypercholesterolaemia is a major risk factor for cardiovascular disease and requires effective therapy in affected patients. Statins, the mainstay of lipid-lowering therapy, can cause side effects, including myalgia, in some patients. Ezetimibe, is frequently used as an add-on therapy for statins, and is also used as a monotherapy in statin-intolerant patients, however elevations in liver transaminases can occur. We examined the lipid-lowering efficacy of the natural fungal product Monascus purpureus (MP), which contains the natural statin monacolin K...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29096865/cascade-screening-for-familial-hypercholesterolemia-practical-consequences
#6
Leonora Louter, Joep Defesche, Jeanine Roeters van Lennep
Familial Hypercholesterolemia (FH) is an autosomal dominant disorder mainly caused by mutations in the LDLR gene, resulting in elevated serum cholesterol levels and elevated risk of premature cardiovascular disease (CVD). Timely treatment with lipid lowering medication can lower the risk of CVD to the same level of the normal population. Currently the incidence of FH is estimated at 1 in 240 persons in the Caucasian population. A diagnosis of FH can be made on the basis of clinical criteria (including LDL cholesterol and family history) or DNA testing...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29096864/care-high-cascade-screening-and-registry-for-high-cholesterol-in-germany
#7
Nina Schmidt, Tanja Grammer, Ioanna Gouni-Berthold, Ulrich Julius, Ursula Kassner, Gerald Klose, Christel König, Ulrich Laufs, Britta Otte, Elisabeth Steinhagen-Thiessen, Christoph Wanner, Winfried März
INTRODUCTION: Familial hypercholesterolemia (FH) is an inherited disorder of the LDL metabolism, leading to cardiovascular disease, even at young age. This risk can be significantly lowered by early diagnosis and treatment. About 270,000 patients affected in Germany are not diagnosed correctly and only a small number is treated properly. To improve FH diagnosis in the general population a cascade screening and registry data is warranted, yet missing in Germany. This project aims to fill this gap...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29096863/lipidological-competence-centres-and-networks-future-perspectives-to-improve-healthcare-of-patients-with-disorders-of-lipid-metabolism
#8
Franz Heigl, Tobias Pflederer, Volker Schettler, Peter Grützmacher, Ulrich Julius, Jens Ringel, Tilmann David-Walek, Reinhard Hettich, Norbert Lotz, Harduin Reeg, Markus Graf, Hans-Ulrich Klör
BACKGROUND: Numerous healthcare studies have shown that more than 90% of all patients with dyslipidaemia are not treated adequately. OBJECTIVES: The "Deutsche Gesellschaft zur Bekämpfung von Fettstoffwechselstörungen und ihren Folgeerkrankungen (DGFF)" [German Society of Lipidology], a non-profit professional membership organization, has already made a series of efforts to improve the care of patients suffering from dyslipidaemia. A recent outcome is the nationwide implementation and certification of Lipidological Competence Centres and Networks (LCCNs)...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29096862/analysis-of-lipid-metabolism-and-its-impact-on-the-risk-of-ischemic-heart-disease-in-patients-with-definite-familial-hypercholesterolemia
#9
Viktoria Korneva, Tatiana Kuznetsova, Ulrich Julius
AIM: to analyze the relationship between lipid disturbance, including lipoprotein(a) (Lp(a)) levels, and development of ischemic heart disease (IHD) in patients with familial hypercholesterolemia (FH). MATERIALS AND METHODS: 81 patients (middle age was 39.1 ± 0.4 years, 33 males, 48 females) with a definite FH were examined. The concentration of Lp(a) was determined by immunoturbidimetric method. Lipid profiles were estimated by enzymatic colorimetric method...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29096861/current-insights-into-the-german-lipoprotein-apheresis-registry-glar-almost-5-years-on
#10
V J J Schettler, C L Neumann, C Peter, T Zimmermann, U Julius, E Roeseler, F Heigl, P Grützmacher, H Blume
BACKGROUND: In recent years the Federal Joint Committee (G-BA), a paramount decision-making body of the German health care system required a reassessment of the approval of chronic lipoprotein apheresis therapy for regular reimbursement. Since 2005 an interdisciplinary German apheresis working group has been established by members of both German Societies of Nephrology. In 2009 the working group completed the indication for lipoprotein apheresis with respect to current cardiovascular guidelines and current scientific knowledge for the registry...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29096860/current-insights-into-the-german-lipoprotein-apheresis-standard-pcsk9-inhibitors-lipoprotein-apheresis-or-both
#11
V J J Schettler, J Ringel, S Jacob, U Julius, R Klingel, F Heigl, E Roeseler, P Grützmacher
According to current European guidelines, lipid lowering therapy for progressive cardiovascular disease including cardiovascular events has to be focused on a target level for LDL-C. In contrast for Lp(a) a threshold has to be defined with respect to the method of measurement. However, due to new lipid lowering drug developments like PCSK9-inhibitors (PCSK-9-I) a therapeutic algorithm for patients with severe hypercholesterolemia or isolated Lipoprotein(a)-hyperlipoproteinemia with progressive cardiovascular disease may be necessary to manage the use of PCSK9-I, lipoprotein apheresis (LA) or both...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29096859/lipoprotein-a-apheresis-in-the-light-of-new-drug-developments
#12
Anja Vogt
Elevated levels of lipoprotein(a) (Lp(a)) contribute to the risk of early and severe cardiovascular disease (CVD). Recently <50 mg/dl was recommended as the desirable level for clinical use and decision making. All established medical therapies to lower cholesterol levels have no impact on lowering Lp(a) except niacin which is all too often poorly tolerated and not obtainable everywhere. Lipoprotein apheresis is an extracorporeal treatment to lower levels of Lp(a) significantly by > 60%. In some countries it is recommended in very high risk patients with early or progressive CVD...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29096858/management-of-patients-with-statin-intolerance
#13
Sabine Fischer, Ulrich Julius
In recent years statins have become an established option in lipid-lowering pharmacotherapy despite the fact that statin intolerance is fairly common. When muscle pains and/or an elevation of the creatine kinase appear, the dose must be lowered in patients with slight symptoms or stopped altogether if the symptoms are more severe. When the symptoms are alleviated and creatine kinase is normalized, re-exposition can be considered. If symptoms recur, treatment with another statin should be attempted - in these cases pravastatin or fluvastatin are recommended, although they are less effective in reducing LDL cholesterol...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29096857/adma-reduction-does-not-protect-mice-with-streptozotocin-induced-diabetes-mellitus-from-development-of-diabetic-nephropathy
#14
Roman N Rodionov, Annett Heinrich, Silke Brilloff, Natalia Jarzebska, Jens Martens-Lobenhoffer, Stefanie M Bode-Böger, Vladimir T Todorov, Christian P M Hugo, Norbert Weiss, Bernd Hohenstein
BACKGROUND AND AIMS: Cardiovascular disease is the major cause of morbidity and mortality in the world. Diabetes and its complications, such as diabetic nephropathy, dramatically increase cardiovascular risk. Association studies suggest that asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthases, plays a role in the pathogenesis of diabetic nephropathy. The major pathway of ADMA catabolism is hydrolysis by dimethylarginine dimethylaminohydrolase 1 (DDAH1)...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29096856/in-vivo-imaging-of-murine-vasodynamics-analyzing-different-mouse-strains-by-optical-coherence-tomography
#15
Gregor Müller, Sven Meissner, Julia Walther, Edmund Koch, Henning Morawietz
BACKGROUND AND AIMS: We tried to circumvent the limitations of standard organ chamber experiments using in vivo optical coherence tomography (OCT) to analyze the vascular function of small arteries in different mouse strains. METHODS: OCT images were acquired with a two-axis galvanometer scanner head. Time series (3 frames per second, 300 × 512 pixel per frame) of cross-sectional images were analyzed with image processing software measuring the time course of vessel lumen dynamics...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29096855/impact-of-omega-3-fatty-acids-on-expression-of-angiogenic-cytokines-and-angiogenesis-by-adipose-derived-stem-cells
#16
Iryna Parshyna, Susann Lehmann, Katrin Grahl, Claudia Pahlke, Annika Frenzel, Helmut Weidlich, Henning Morawietz
BACKGROUND AND AIMS: Human adipose-tissue derived stem cells (ADSC) are interesting novel targets in tissue engineering and regenerative medicine with pronounced angiogenic capacities. Furthermore, omega-3 fatty acids have been described to mediate cardioprotective effects, but their role in angiogenesis and vascular regeneration is not well-understood. Here, we analyzed the impact of different omega-3 fatty acids on angiogenesis by ADSCs. METHODS: Stem cells were cultured as monolayers or in 3D models, in spheroids embedded in collagen matrix or in co-cultures with human umbilical vein endothelial cells (HUVECs) in the Matrigel™ assay...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29096854/lectin-like-oxidized-low-density-lipoprotein-receptor-1-promotes-endothelial-dysfunction-in-ldl-receptor-knockout-background
#17
Anja Hofmann, Coy Brunssen, David M Poitz, Heike Langbein, Ruth H Strasser, Thomas Henle, Ursula Ravens, Henning Morawietz
OBJECTIVE: Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is the major receptor for oxidized LDL in endothelial cells. LOX-1 is highly expressed in atherosclerotic plaques. The impact of LOX-1 on development of endothelial dysfunction in large vessels in absence or presence of atherosclerosis-prone conditions has not been studied to date. METHODS: Mice with endothelial cell-specific LOX-1 overexpression (bLOX-1tg) were analyzed. Wild-type (WT) mice served as controls...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29096853/plasma-filtration-for-the-controlled-removal-of-liposomal-therapeutics-from-the-apheretic-site-of-view
#18
M Blaha, J Martinkova, M Lanska, S Filip, J Malakova, O Kubecek, J Bezouska, J Spacek
INTRODUCTION: Nanoparticle-based drug delivery systems can overcome the dose-limited toxicity of cytostatics. Pegylated doxorubicin-containing liposomes (PLD) are able to reduce cardiotoxicity. PLD quickly (in 2 days) attains therapeutic concentration in tumorous tissue (kinetic targeting), while its distribution in normal tissue, which is a cause of mucocutaneous toxicity (MCT), is delayed. We examined PLD extracorporeal removal effectivity, using plasma filtration (PF) to determine whether the drug could be withheld prior to its organ distribution responsible for MCT toxicity...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29096852/therapeutic-plasma-exchange-in-a-rare-case-myasthenic-crisis-after-botox-injection
#19
Azita Chegini
BACKGROUND AND AIMS: Botulinum toxin (Botox) injections are used as a cosmetic treatment to decrease wrinkles in face and chin. Being a neurotoxic agent it minimizes muscle activity, while side effects are usually rare. This article subsequently presents one case of these rare effects. CASE: A 30-year-old woman presenting with ptosis, diplopia, dysarthria, dysphagia and muscle weakness was admitted to our hospital. She had no history of disease. For cosmetic reasons, she had three Botox injections during the preceding months...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29096851/how-effectively-will-pcsk9-inhibitors-allow-retrieval-of-freedom-from-apheresis-in-cardiovascular-high-risk-patients-estimates-form-a-large-single-center
#20
Bernd Hohenstein, Sergey Tselmin, Stefan R Bornstein, Ulrich Julius
Lipoprotein apheresis (LA) has been the last-resort therapeutic option in patients suffering from limited pharmaceutical options to lower highly elevated low density lipoprotein cholesterol (LDL-C) levels. Facing the introduction of the proprotein convertase subtilisin/kexine type 9 (PCSK-9) inhibitors, it has been speculated that they might replace LA to a large extend. Given an efficacy of approx. 55-65% to lower LDL-C it is important to analyze whether this might be realistic i) for potential candidates in apheresis sites and ii) for the future structures of the sites themselves...
November 2017: Atherosclerosis. Supplements
journal
journal
38114
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"